ArticleCancer reports (Hoboken, N.J.)2025
DHCR7 as a Prognostic and Immunological Biomarker in Human Pan-Cancer: A Comprehensive Evaluation.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DHCR7 as a Prognostic and Immunological Biomarker in Human Pan-Cancer: A Comprehensive Evaluation.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe 7-Dehydrocholesterol reductase (DHCR7), a critical enzyme catalyzing the final step of the cholesterol biosynthesis pathway, has gained attention for its potential role in tumorigenesis. This study systematically investigated the association between DHCR7 expression and oncogenic processes across multiple cancer types.
methodsMulti-omics data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) repositories. DHCR7 expression patterns were analyzed using Oncomine, TIMER, and GEPIA platforms. Prognostic significance was assessed via Kaplan-Meier plotter and GEPIA. Tumor stage correlations and immune/molecular subtype associations were evaluated using TISIDB. SangerBox facilitated analysis of DHCR7's associations with immune checkpoint (ICP) molecules, tumor mutational burden (TMB), microsatellite instability (MSI), mutant-allele tumor heterogeneity (MATH), neoantigen load, and immune cell infiltration.
resultsDHCR7 exhibited significant overexpression in most malignancies, correlating with advanced tumor stage (p < 0.05), metastatic progression, and reduced overall survival (HR = 1.34, 95% CI: 1.18-1.52). Strong associations emerged between DHCR7 expression and critical immunomodulatory parameters: positive correlations with ICPs (PD-L1: r = 0.62, CTLA4: r = 0.58). Significant links to TMB (p = 2.1e-5), MSI (p = 4.3e-4), and MATH (p = 7.8e-3). Distinct immune infiltration patterns, particularly in bladder carcinoma (BLCA), renal clear cell carcinoma (KIRC), and prostate adenocarcinoma (PRAD). Co-expression network analysis revealed DHCR7's involvement in immune response regulation (GO:0002764, FDR = 0.003), leukocyte differentiation (GO:0002521, FDR = 0.012), and angiogenesis (GO:0001525, FDR = 0.018).
conclusionsThese pan-cancer analyses identify DHCR7 as a multifaceted biomarker with dual prognostic and immunotherapeutic relevance. Its involvement in tumor immune microenvironment modulation suggests potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.